Discovery of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives as novel ENPP1 inhibitors

Bioorg Med Chem Lett. 2022 Nov 1:75:128947. doi: 10.1016/j.bmcl.2022.128947. Epub 2022 Aug 19.

Abstract

Ectonucleotide pyrophosphatase/phosphodiesterase-1 (ENPP1) negatively regulates the anti-cancer Stimulator of Interferon Genes (STING) pathway. We discovered that 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one and 3,4-dihydropyrido[2,3-d]pyrimidin-2(1H)-one derivatives possessed inhibitory activities on ENPP1. A structure-activity relationship (SAR) study led to the identification of 46 and 23 as potent ENPP1 inhibitors. Also, compounds 46 and 23 possessed high microsomal stabilities in human, rat, and mouse liver microsome. Additionally, CYPs (1A2, 2C9, 2C19, 2D6, and 3A4) were not inhibited by 46 and 23. Molecular dynamics simulations provided an insight of binding modes between ENPP1 and compounds (46 and 23).

Keywords: Cancer immunotherapy; ENPP1; Innate immunity; STING.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Humans
  • Interferons
  • Mice
  • Microsomes, Liver / metabolism
  • Phosphoric Diester Hydrolases* / metabolism
  • Pyrophosphatases*
  • Rats
  • Structure-Activity Relationship

Substances

  • Interferons
  • Phosphoric Diester Hydrolases
  • Pyrophosphatases